Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 14;15(1):3.
doi: 10.1186/s11689-022-09468-4.

Longitudinal neurobehavioral profiles in children and young adults with PTEN hamartoma tumor syndrome and reliable methods for assessing neurobehavioral change

Affiliations

Longitudinal neurobehavioral profiles in children and young adults with PTEN hamartoma tumor syndrome and reliable methods for assessing neurobehavioral change

Robyn M Busch et al. J Neurodev Disord. .

Abstract

Background: Individuals with PTEN hamartoma tumor syndrome (PHTS) demonstrate a distinct neurobehavioral profile suggesting primary disruption of frontal lobe symptoms, with more severe cognitive deficits in those with associated autism spectrum disorder (ASD) that extend to other areas of neurobehavioral function as well (e.g., adaptive behavior, sensory deficits). The current study sought to characterize longitudinal neurobehavioral profiles in individuals with PHTS who completed serial assessments (2-3 evaluations) over a 2-year time period.

Methods: Comprehensive neurobehavioral evaluations were conducted on 92 participants (age range 6-21) with PHTS and/or ASD. Spaghetti plots and linear mixed effects models were used to visualize the individual patient profiles and group trends and examine the group differences in cognitive/behavioral test scores over time. Practice-adjusted reliable change indices (RCIs) and standardized regression-based change scores (SRBs) were calculated for those measures in the battery with adequate sample sizes and test-retest reliabilities for future use in assessing neurobehavioral change in children and young adults with PHTS.

Results: Wide individual differences were observed at baseline across all measures. Encouragingly, baseline differences between patient groups persisted at the same magnitude over a 2-year time period with no differences in longitudinal neurobehavioral profiles within any one group. Test-retest reliabilities were generally high, ranging from 0.62 to 0.97, and group mean change from baseline to 12 months was small (range - 3.8 to 3.7). A Microsoft Excel calculator was created that clinicians and researchers can use to automatically calculate RCI and SRB thresholds at both 80% and 90% confidence intervals using test scores from a given child or young adult with PHTS.

Conclusions: Our results suggest that the neurobehavioral phenotypes observed in individuals with PHTS remain relatively stable over time, even in those with ASD. The RCIs and SRBs provided can be used in future research to examine patient outcomes at the individual level as well as to detect negative deviations from the expected trajectory that can be used to inform intervention strategies.

Keywords: Autism spectrum disorder; Behavior; Cognition; PTEN; PTEN hamartoma tumor syndrome; Reliable change indices; Standardized regression-based change scores.

PubMed Disclaimer

Conflict of interest statement

Dr. Busch, Ms. Sonneborn, Ms. Hogue, Dr. Klaas, Dr. Srivastava, Dr. Hardan, Dr. Martinez-Agosto, and Dr. Eng declare that they have no competing interests.

Dr. Frazier has received funding or research support from, acted as a consultant to, received travel support from, and/or received a speaker’s honorarium from the PTEN Research Foundation, SYNGAP Research Fund, Malan Syndrome Foundation, ADNP Kids Research Foundation, Quadrant Biosciences, Autism Speaks, Impel NeuroPharma, F. Hoffmann-La Roche AG Pharmaceuticals, the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol-Myers Squibb, Roche Pharma, MaraBio, National Institutes of Health, and the Brain and Behavior Research Foundation and has an investor stake in Autism EYES LLC.

Dr. Sahin reports grant support from Novartis, Biogen, Astellas, Aeovian, Bridgebio, and Aucta. He has served on Scientific Advisory Boards for Novartis, Roche, Regenxbio, SpringWorks Therapeutics, Jaguar Therapeutics, and Alkermes, all unrelated to this project.

Figures

Fig. 1
Fig. 1
Longitudinal performance on cognitive measures. Spaghetti plots depicting cognitive performance over time on select cognitive measures. A Stanford-Binet Intelligence Scales Full Scale IQ. B Sanford-Binet Intelligence Scales Working Memory Index. C Wechsler Intelligence Scale for Children – Fifth Edition Processing Speed Index. D Expressive Vocabulary Test. Each gray line represents a single subject, while each colored line represents the group trend over time (blue: PTEN-no ASD; red: Macro-ASD; green: PTEN-ASD). Fragmented subject lines indicate the partial follow-up data

References

    1. Marsh DJ, Kum JB, Lunetta KL, Bennett MJ, Gorlin RJ, Ahmed SF, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet. 1999;8:1461–1472. doi: 10.1093/hmg/8.8.1461. - DOI - PubMed
    1. Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer. 2007;7:35–45. doi: 10.1038/nrc2037. - DOI - PubMed
    1. Busch RM, Chapin JS, Mester J, Ferguson L, Haut JS, Frazier TW, Eng C. Cognitive characteristics of PTEN hamartoma tumor syndromes. Genet Med. 2013;15:548–553. doi: 10.1038/gim.2013.1. - DOI - PMC - PubMed
    1. Frazier TW, Embacher R, Tilot AK, Koenig K, Mester J, Eng C. Molecular and phenotypic abnormalities in individuals with germline heterozygous PTEN mutations and autism. Mol Psychiatry. 2015;20:1132–1138. doi: 10.1038/mp.2014.125. - DOI - PMC - PubMed
    1. Busch RM, Srivastava S, Hogue O, Frazier TW, Klaas P, Hardan A, et al. Neurobehavioral phenotype of autism spectrum disorder associated with germline heterozygous mutations in PTEN. Transl Psychiatry. 2019;9:253. doi: 10.1038/s41398-019-0588-1. - DOI - PMC - PubMed

Publication types